柔木丹改善小鼠肝纤维化的TGF-β1/Smad4信号通路机制*

doi:10.12047/j.cjap.6010.2020.121

中国应用生理学杂志 ›› 2020, Vol. 36 ›› Issue (6): 576-581.doi: 10.12047/j.cjap.6010.2020.121

柔木丹改善小鼠肝纤维化的TGF-β1/Smad4信号通路机制^*

李倩¹, 闫曙光², 惠毅², 李京涛³, 魏海梁³, 张红^1,2△

1.陕西中医药大学医学科研实验中心, 咸阳 712046;
2.陕西中医药大学基础医学院, 咸阳 712046;
3.陕西中医药大学附属医院, 咸阳 712000

收稿日期:2020-01-19 修回日期:2020-11-25 出版日期:2020-11-28 发布日期:2021-03-15
通讯作者: ^△Tel: (029)38183453; E-mail: zhangh1227@163.com
基金资助:
^*陕西省自然科学基础研究计划(2020JQ-864);陕西省教育厅科学研究项目(17JK0216);陕西省中药基础与新药研究重点实验室开放基金项目(2017KF07);陕西中医药大学学科创新团队建设项目(2019-YL05);陕西中医药大学科研基金项目(2016QN30)

Roumudan formulation attenuated liver fibrosis by inhibiting TGF-β1/Smad4 pathway in mice

LI Qian¹, YAN Shu-guang², HUI Yi², LI Jing-tao³, WEI Hai-liang³, ZHANG Hong^1,2△

1. Medical Experiment Center, Shaanxi University of Chinese Medicine, Xianyang 712046;
2. Department of Pathophysiology, Shaanxi University of Chinese Medicine, Xianyang 712046;
3. Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China

Received:2020-01-19 Revised:2020-11-25 Online:2020-11-28 Published:2021-03-15

摘要/Abstract

摘要： 目的:探讨柔木丹(RMD)对改善CCl₄诱导的小鼠肝纤维化的TGF-β1/果蝇抗生物皮肤生长因子蛋白家族4号因子(Smad4)信号通路机制。方法:雄性BALB/c小鼠随机分为空白对照组、模型组、RMD治疗组(n=11)。腹腔注射CCl₄诱导小鼠肝纤维化模型,模型及RMD治疗组小鼠腹腔注射20 % CCl₄(CCl₄∶橄榄油=1∶4),注射量为2.5 ml/kg,空白对照组以同样方法注射等量橄榄油,每周2次;第2周起调整模型及RMD治疗组小鼠CCl₄腹腔注射量为5 ml/kg(空白对照组注射等量橄榄油),每周2次。成模后,RMD治疗组小鼠使用RMD灌胃给药(6.2 g/(kg·d);空白对照组、模型组使用等量的水灌胃),模型及RMD治疗组小鼠继续腹腔注射20 % CCl₄,注射量为1.5 ml/kg(空白对照组注射等量橄榄油),每周1次,持续3 周。采取各组小鼠血清样本检测谷丙转氨酶(ALT)、谷草转氨酶(AST)活性;采取各组小鼠肝组织样本使用HE、Masson、原位杂交、免疫组织化学染色、Western blot、Q-PCR等方法进行检测。结果:与正常组相比,CCl₄造模5 周后,模型组小鼠肝脏纤维化病理特征明显。与模型组相比,RMD治疗3 周,治疗组小鼠肝组织病理学改变减轻,小鼠的肝脏指数(P＜0.01)、血清中的ALT(P＜ 0.01)、AST(P＜0.01)活性、肝组织中羟脯氨酸的含量(P＜0.05)均降低;Ⅰ型胶原(Collagen Ⅰ,P＜0.01)、Ⅲ型胶原(Collagen Ⅲ,P＜0.01)表达减少,胶原沉积减少;肝组织中TGF-β1(P＜0.05)和α-SMA(P＜0.05)表达均降低;肝组织中Smad4阳性表达区域缩小、表达强度降低。结论:RMD通过抑制TGF-β1/Smad4通路信号转导,减少胶原沉积,进而发挥抗小鼠肝纤维化的作用。

关键词: 纤维化, 肝, 柔木丹, 四氯化碳, 小鼠

Abstract: Objective: To investigate underlying mechanism involving Roumudan(RMD) formulation (Z20160012) suppressed liver fibrosis induced by CCl₄ injection in mice by inhibiting TGF-β1/Smad4 pathway. Methods: Male BALB/c mice were randomly divided into control group, liver fibrosis model group and RMD-treated group(n=11). Mice in liver fibrosis model and RMD-treaded groups were injected intraperitoneally with CCl₄ (20% in olive oil) at the dose of 2.5 mL/kg two times for one week and 5 mL/kg two times for 4 weeks. Mice in control group were treated intraperitoneally with the same volume of olive oil at the same time intervals. From sixth week, Mice in liver fibrosis model group were administrated with CCl₄ (20% in olive oil, 1.5 ml/kg once per week) intraperitoneally and given distilled water by intragastric gavage. Mice in the RMD-treated group were administrated with CCl₄ (20% in olive oil, 1.5 ml/kg/mouse once per week) intraperitoneally and given RMD(6.2 g/kg everyday) by intragastric gavage. Mice in the control group were administrated with olive oil (1.5 ml/kg/mouse once per week) intraperitoneally and given distilled water by intragastric gavage. The serum AST and ALT levels were estimated for assessment of liver function. The pathologic changes of mice' livers were examined by the HE, Masson, immunohistochemical staining, Western Blot, Q-PCR and so on. Results: After intraperitoneally injected with CCl₄ in mice, the pathological characteristics of liver fibrosis were observed compared with the control group at the sixth week. Compared with the liver fibrosis model group, RMD improved the liver function significantly through reducing liver index(P＜0.01) and the levels of ALT(P＜0.01), AST(P＜0.01) and HYP(P＜0.05). The expression of TGF-β1(P＜0.05), α-SMA(P＜0.05), COL1A1(P＜0.01) and COL3A1(P＜0.01) were decreased by RMD. The positive expression area of Smad4 mRNA in RMD treated group was lower than that in liver fibrosis model group. Conclusion: The RMD formulation could attenuate liver fibrosis by inhibiting TGF-β1/Smad4 pathway and extracellular matrix (ECM) production in mice.

Key words: fibrosis, liver, roumudan, carbon tetrachloride, mice

中图分类号:

R256.42

李倩, 闫曙光, 惠毅, 李京涛, 魏海梁, 张红. 柔木丹改善小鼠肝纤维化的TGF-β1/Smad4信号通路机制^*[J]. 中国应用生理学杂志, 2020, 36(6): 576-581.

LI Qian, YAN Shu-guang, HUI Yi, LI Jing-tao, WEI Hai-liang, ZHANG Hong. Roumudan formulation attenuated liver fibrosis by inhibiting TGF-β1/Smad4 pathway in mice[J]. CJAP, 2020, 36(6): 576-581.

参考文献

[1] Duran A, Hernandez ED, Reina-Campos M, et al. p62/SQSTM1 by binding to vitamin D receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer[J]. Cancer Cell, 2016, 30(4): 595-609.
[2] Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis[J]. Advanced drug delivery reviews, 2017, 121: 27-42.
[3] Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer[J]. Annu Rev Pathol, 2017, 12: 153-186.
[4] 王志旺, 付晓艳, 程小丽, 等. 育阴软肝颗粒剂对肝纤维化大鼠TGF-β1表达的影响[J].中国应用生理学杂志, 2018, 34(2): 169-172.
[5] Zhang X, Xu Y, Chen JM, et al. Huang Qi decoction prevents BDL-induced liver fibrosis through inhibition of notch signaling activation[J]. Am J Chin Med, 2017, 45(1): 85-104.
[6] 席奇, 刘宝咸, 刘亚珠, 等. 柔木丹颗粒治疗乙型肝炎肝纤维化随机对照研究[J]. 现代中西医结合杂志, 2016, 25(36): 3991-3993.
[7] 席奇, 刘亚珠, 宋春荣, 等. 柔木丹颗粒联合恩替卡韦治疗乙型肝炎肝纤维化45例疗效观察[J]. 中医药导报, 2015, 21(24): 46-48.
[8] 史晓燕, 许小凡, 宋亮, 等. 柔木丹颗粒对四氯化碳诱导小鼠肝纤维化的治疗作用[J]. 新乡医学院学报, 2019, 36(1): 1-6.
[9] 汪小玲, 杨红侠, 刘芸, 等. 柔木丹颗粒质量标准的研究[J]. 陕西中医学院学报, 2009, 32(1): 62-63.
[10] 黄继汉, 黄晓晖, 陈志扬, 等. 药理试验中动物间和动物与人体间的等效剂量换算[J]. 中国临床药理学与治疗学, 2004, 9(9): 1069-1072.
[11] 邓莉, 申宝德, 刘园, 等. 复方鳖甲软肝片减方对CCl₄诱导大鼠肝纤维化的影响及机制研究[J]. 中草药, 2018, 49(6): 1371-1378.
[12] 庄子锐, 王明亮, 张婷, 等. 肝肾纤维化动物模型的研究进展及评价[J/OL]. 中国实验动物学报, 2020: 1-8(2020-11-26).
[13] 肖敏, 屈小虎, 吕聚坪, 等. 吡非尼酮对四氯化碳诱导的小鼠肝纤维化的影响[J]. 中国应用生理学杂志, 2016, 32(4): 378-382.
[14] Huang Y, Deng X, Liang J. Modulation of hepatic stellate cells and reversibility of hepatic fibrosis[J]. Exp Cell Res, 2017, 352(2): 420-426.
[15] Watanabe T, Niioka M, Hozawa S, et al. Gene expression of interstitial collagenase in both progressive and recovery phase of rat liver fibrosis induced by carbon tetrachloride[J]. J Hepatol, 2000, 33(2): 224-235.
[16] Xu F, Liu C, Zhou D, et al. TGF-beta/SMAD pathway and its regulation in hepatic fibrosis[J]. J Histochem Cytochem, 2016, 64(3): 157-167.
[17] Yoshida K, Murata M, Yamaguchi T, et al. TGF-β/Smad signaling during hepatic fibro-carcinogenesis[J]. Int J Oncol, 2014, 45(4): 1363-1371.
[18] Zou Y, Cai Y, Lu D, et al. MicroRNA-146a-5p attenuates liver fibrosis by suppressing profibrogenic effects of TGF-β1 and lipopolysaccharide[J]. Cell Signal, 2017, 39: 1-8.
[19] Wu X, Wu X, Ma Y, et al. CUG-binding protein 1 regulates HSC activation and liver fibrogenesis[J]. Nature Communications, 2016, 7(13498): 1-14.
[20] Bruschi FV, Claudel T, Tardelli M, et al. The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells[J]. Hepatology, 2017, 65(6): 1875-1890.

柔木丹改善小鼠肝纤维化的TGF-β1/Smad4信号通路机制^*

Roumudan formulation attenuated liver fibrosis by inhibiting TGF-β1/Smad4 pathway in mice

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈龙, 杨玉琪, 冯子奕, 李雪蕊, 韩子伟, 马克涛, 司军强, 李丽. 雌激素对老年C57BL/6J小鼠耳蜗螺旋神经节细胞凋亡的影响^*[J]. 中国应用生理学杂志, 2020, 36(6): 529-533.
[2]	王丹, 高峰, 陈慧, 项伟玲, 骆志显, 金丽琴. 人参归脾丸对脾不统血证大鼠肝损伤的保护作用及其机制^*[J]. 中国应用生理学杂志, 2020, 36(6): 571-575.
[3]	韦凌霞, 丁茂鹏, 王志旺, 刘雪枫, 庞亚蓉, 郭玫. 鳖甲育肝颗粒对乙醇性肝纤维化大鼠的影响^*[J]. 中国应用生理学杂志, 2020, 36(6): 582-586.
[4]	邵一帆, 张安琪, 陈天姣, 李海北, 陈郑珊, 尹静, 杨栋, 师丹阳, 梁永兵, 程春燕, 谭蓉, 孙栋良, 李君文, 金敏. 高效液相色谱串联质谱法同时检测粪便中三种抗抑郁药物^*[J]. 中国应用生理学杂志, 2020, 36(6): 668-672.
[5]	李杰茹, 任静, 杨胜昌, 韩聚强, 郭亚净, 吉恩生. 消痰化瘀利窍中药组方对改善慢性间歇性低氧大鼠心肌纤维化的作用及其机制^*[J]. 中国应用生理学杂志, 2020, 36(5): 414-418.
[6]	赵波, 魏海萍. 利格列汀对小鼠脑缺血/再灌注损伤的神经保护作用^*[J]. 中国应用生理学杂志, 2020, 36(5): 452-455.
[7]	姬瑞方, 卞学鹏, 刘蓓蓓, 胡静芸, 薛香莉, 娄淑杰. 抗阻运动对胰岛素抵抗小鼠海马内焦亡相关蛋白的影响^*[J]. 中国应用生理学杂志, 2020, 36(5): 456-461.
[8]	肖楚丽, 滕林, 李金成, 肖煦晖, 于旭东. 对香豆酸对慢性束缚应激诱导小鼠抑郁样行为的作用^*[J]. 中国应用生理学杂志, 2020, 36(5): 485-488.
[9]	赵家荣, 冯雪松, 李宏, 王国全, 张艳芳, 史海龙, 李媛媛, 晁旭. 四逆散对人肝癌HepG2细胞增殖、凋亡的影响及其机制^*[J]. 中国应用生理学杂志, 2020, 36(5): 489-493.
[10]	胡泉东, 杨玉娟, 余珊珊. 脂氧素受体激动剂BML-111对大鼠急性肝损伤的干预作用及其机制^*[J]. 中国应用生理学杂志, 2020, 36(5): 494-498.
[11]	程小丽, 赵余珠, 王志旺, 丁茂鹏, 韦凌霞, 潘虹. 七味育肝颗粒对肝纤维化大鼠的防治作用^*[J]. 中国应用生理学杂志, 2020, 36(5): 499-502.
[12]	付学东, 王寿懿, 朱志强, 邓幼平. 微小核糖核酸106b对肝细胞葡萄糖异生的影响及机制^*[J]. 中国应用生理学杂志, 2020, 36(5): 503-508.
[13]	席雨鑫, 温馨, 矫立杰, 魏亚新, 常贵全, 武韧, 孙凤起, 郝静辉, 李鸿珠. 外源性H₂S对糖尿病小鼠肝纤维化的作用及其机制^*[J]. 中国应用生理学杂志, 2020, 36(4): 318-320.
[14]	田香勤, 谭朝阳, 李娜娜, 常玉巧, 张爱梅, 周颖, 马克涛, 司军强. 钙激活氯通道蛋白ANO1在心肌成纤维细胞分化过程中的表达及其钙激活氯通道电生理特性变化^*[J]. 中国应用生理学杂志, 2020, 36(4): 358-362.
[15]	肖楚丽, 谢一铭, 李金成, 彭丽文, 肖志勇, 于旭东. 对香豆酸上调BDNF及改善慢性束缚应激诱导小鼠记忆障碍的作用^*[J]. 中国应用生理学杂志, 2020, 36(4): 375-378.